Organon & Co. (NYSE:OGN) to Issue $0.28 Quarterly Dividend

Organon & Co. (NYSE:OGN) declared a quarterly dividend on Thursday, February 13th, Wall Street Journal reports. Investors of record on Monday, February 24th will be given a dividend of 0.28 per share on Thursday, March 13th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.24%. The ex-dividend date of this dividend is Monday, February 24th.

Organon & Co. has increased its dividend by an average of 26.0% per year over the last three years. Organon & Co. has a dividend payout ratio of 26.7% meaning its dividend is sufficiently covered by earnings. Research analysts expect Organon & Co. to earn $3.74 per share next year, which means the company should continue to be able to cover its $1.12 annual dividend with an expected future payout ratio of 29.9%.

Organon & Co. Stock Performance

Organon & Co. stock opened at $15.47 on Friday. The stock has a 50-day simple moving average of $15.36 and a 200 day simple moving average of $17.28. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. Organon & Co. has a 12-month low of $13.87 and a 12-month high of $23.10. The stock has a market capitalization of $3.98 billion, a price-to-earnings ratio of 4.64, a P/E/G ratio of 0.90 and a beta of 0.76.

Organon & Co. (NYSE:OGN) last released its quarterly earnings results on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The business had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.57 billion. On average, research analysts anticipate that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently commented on OGN shares. TD Cowen upgraded Organon & Co. to a “hold” rating in a research report on Wednesday, January 15th. Morgan Stanley lowered their price objective on Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating for the company in a research report on Friday, February 14th. Finally, Barclays lowered their price objective on Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Organon & Co. has an average rating of “Hold” and an average price target of $20.80.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.